about
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemiaTargeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.The impact of SF3B1 mutations in CLL on the DNA-damage response.The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia[Molecular Prognostic Markers and Their Clinical Relevance in Chronic Lymphocytic Leukemia]Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients
P50
Q27853022-60D470B0-4C8F-4192-8207-B9E1E07DF9EAQ28303339-DE249B62-BF79-4BDF-803F-3C13ABE9C926Q35146301-348616C7-B00D-4AEE-B79B-BC2C178A4756Q36022313-C5800A38-21D0-4730-8CAE-BE84CACCA515Q36967158-99E02FF6-B4AB-4F66-970F-F5DA9C9C3501Q40455172-DC31FC6E-5F9F-4B07-89DB-F4B2C3F907F9Q42384352-8B2348B2-DFA8-4BE3-B9C4-7FCCE5713636Q42399864-C74A02C5-39C7-48C1-9C29-DAA604221E36Q44290485-913D3D0D-1EC6-4BD6-9D2F-F08F05784492Q46603893-A630D8C6-FFB9-4858-9FF4-34ACE9B69C1BQ53516167-C02DD63D-F7E3-4F5F-B15D-1051BBBE4CE6Q54191292-58C5C2DF-44D7-4361-B259-B36D1E44755CQ83292194-EBFE1C0F-8E21-4E76-8629-D854AAC5CC95Q86531735-049B1809-4E29-44FF-8109-6A488CBC9AF8Q88018511-EAE897A5-0B26-4083-A840-0E731B446632
P50
description
buněčná bioložka
@cs
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
V Navrkalova
@ast
V Navrkalova
@es
V Navrkalova
@nl
V Navrkalova
@sl
Veronika Navrkalova
@en
Veronika Navrkalová
@cs
type
label
V Navrkalova
@ast
V Navrkalova
@es
V Navrkalova
@nl
V Navrkalova
@sl
Veronika Navrkalova
@en
Veronika Navrkalová
@cs
prefLabel
V Navrkalova
@ast
V Navrkalova
@es
V Navrkalova
@nl
V Navrkalova
@sl
Veronika Navrkalova
@en
Veronika Navrkalová
@cs
P21
P31
P496
0000-0003-3020-1578